Pfizer Buys FoldRx for Rare Disease Division

Pfizer scoops up FoldRx, a Cambridge-based biotech poised for regulatory review of their lead neurodegenerative drug, tafamadis, targeting amyloid-based diseases.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail